Premium
Thrombotic microangiopathy and retroviral infections: A 13‐year experience
Author(s) -
Ucar Antonio,
Fernandez Hugo F.,
Byrnes John J.,
Lian Eric CY,
Harrington William J.
Publication year - 1994
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830450407
Subject(s) - thrombotic microangiopathy , medicine , human immunodeficiency virus (hiv) , microangiopathy , viral disease , virus , immunopathology , sida , immunology , antibody , virology , gastroenterology , diabetes mellitus , disease , endocrinology
Eleven of fifty serum samples collected from patients with a diagnosis of thrombotic microangiopathy (TMA), from 1979 to 1991, tested positive for antlretroviral antibodies. Seven had human immunodeficiency virus (HIV) infection, and four had human iymphotrophic virus, type I (HTLV‐I) infection. All patients were treated with plasma exchange and for infusion, but only two of the HIV‐infected patlents obtained a complete response (CR) and one of them died after a few months. Combined results from the ilterature indicate that most patients with HIV infection survive less than one year from the initial diagnosis of TMA. In the setting of HIV infection, TMA Is a treatable condition, but survivai for most patients is less than 12 months. Three of the four HTLV‐I infected patients with TMA had a CR. These observations strongly suggest that both HIV and HTLV‐I infections are associated with TMA, but rigorous epidemiologic studies will be needed to determine the relative risk for each. Retrovirai Infections should be considered In patients with TMA, especially If the patient has associated risk factors and demographic characteristics. © 1994 Wiley‐Liss, Inc.